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Abstract
Antigen- and adjuvant-based bioconjugates that can stimulate the immune system play an 
important role in vaccine applications. Bioconjugates have demonstrated unique physicochemical 
and biological properties, enabling vaccines to be delivered to key immune cells, to target specific 
intracellular pathways, or to mimic immunogenic properties of natural pathogens. In this review 
we highlight recent advances in such molecular immunomodulators, with an emphasis on the 
structure-function relationships that provide the foundation for rational design of safe and 
effective vaccines and immunotherapies.
1. Introduction
Vaccines remain the single most effective public health intervention ever developed, with 
millions of lives saved every year through the array of pediatric and adult vaccines 
administered globally.1-3 The immune response elicited by vaccination is a multi-step, 
complex process that involves the coordinated action of diverse molecular signals and 
immune cells within lymphoid organs4,5: first, antigen must be acquired by specialized 
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sentinel cells known as antigen presenting cells (APCs). APCs can internalize antigen 
directly in the tissue of the vaccination site or antigen can be transported through the 
capillary lymphatic vessels to APCs or B-cells in the draining lymph nodes6 (Fig. 1). 
Second, for T-cell activation, these APCs must degrade the antigen in appropriate 
intracellular compartments and load resulting peptide fragments onto major 
histocompatibility complex (MHC) molecules.4,5 These APCs must also be activated by 
inflammatory cues (“danger signals”) elicited by the vaccine, which instruct the APCs to 
mount an immune response against the acquired antigen.7 Third, in the lymph node, CD8+ 
T-cells and CD4+ T-cells with matching receptors recognize peptide fragments from the 
antigen bound to MHC on APC surfaces, and if the APCs are properly activated, these T-
cells proliferate and differentiate into primed effector cells that can directly kill infected 
cells (CD8+ “killer” T-cells) or secrete cytokines to coordinate microbe clearance by other 
immune cells (CD4+ “helper” T-cells). In parallel, antigen is also recognized by antigen-
specific B-cells, which receive “help” signals from primed CD4+ T-cells to differentiate into 
antibody-producing plasma cells that secrete copious amounts of antibody that will bind to 
microbes and promote their clearance. For therapeutic vaccines administered in the presence 
of ongoing disease, these effector T- and B-cell responses can provide immediate 
therapeutic benefit. Following initial expansion, most (~90%) of the antigen-specific CD8+ 
T-cells, CD4+ T-cells, and B-cells generated during this early effector phase die off, but a 
population of long-lived memory T-cells and B-cells develops. This pool of long-lived cells, 
which can persist for many years in humans, is the basis of prophylactic vaccination; these 
memory cells provide in some cases lifelong immunity against subsequent exposure to the 
pathogen matching the vaccine antigen.4
The first licensed vaccines were comprised of inactivated or attenuated live microorganisms. 
Though these whole-microbe vaccines have been successful in preventing many infectious 
diseases, this approach is not applicable to some vaccine settings (e.g., therapeutic vaccines 
for cancer) or may not be safe (e.g., vaccines for HIV). Further, most live-attenuated 
vaccines were developed empirically without a clear understanding of their mechanisms of 
action.8 In the modern era, the paramount importance of vaccine safety has made such an 
approach problematic, and much of current vaccinology is based on the development of 
subunit vaccines, which replace whole microbes with defined protein or polysaccharide 
antigens that have no potential for infectivity or toxicity on their own.9,10 Subunit vaccines 
are usually fully synthetic and have molecularly defined structures, which have advantages 
in manufacturability, stability, and safety. However, subunit vaccines are poorly 
immunogenic and require adjuvants to induce an adaptive immune response. Adjuvants 
broadly defined are any substance added to a vaccine to augment the immune response to 
the antigen, and include diverse compounds including microbe-derived products that trigger 
conserved pathogen-recognition receptors; synthetic immunostimulatory molecules; and 
nanoparticles, microparticles, or oil/water emulsions.11,12
Among these different approaches, one of the most attractive strategies to achieve well-
defined molecular vaccines is to incorporate additional functionality directly into the antigen 
(or alternatively, into danger signal molecules) through bioconjugation.13-16 In fact, 
bioconjugates have long had an important role in the development of vaccines against 
infection, cancer and many other diseases. The most common bioconjugates are those where 
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vaccine components are covalently linked to a protein, peptide, lipid, oligonucleotide, 
polymer, or nanoparticle, but in some cases antigens or molecular adjuvants are linked to 
synthetic small molecules.17-19 Depending on their chemical and molecular nature, 
bioconjugates can enhance vaccine efficacy via diverse mechanisms. Examples include 
conjugation of antigen/adjuvant to a ligand to enable tissue/cell specific targeting; 
conjugation of vaccines to polymers to provide new properties such as multivalency and/or 
controlled release; vaccines conjugated to nanoparticles can also lead to changes in the 
pathways by which antigens are processed by APCs. Thus, bioconjugates can be tailored and 
functionalized according to vaccine-specific needs.
In this review, we summarize bioconjugate strategies being explored in preclinical research 
and clinical development, with a focus on the guiding principles for rational design of 
bioconjugates in vaccine applications. We have chosen to limit the scope to techniques and 
approaches that can modulate the immune system via molecular conjugates; therefore, a 
variety of important and novel systems, such as antigen/adjuvant encapsulated in nano/micro 
particles that have been reviewed recently20,23 are not covered here. In addition, we will not 
discuss polysaccharide/peptide/hapten conjugate vaccines (antigen conjugated to carrier 
proteins), which have also been recently reviewed.15, 24-26
2. Targeting vaccines to the lymphatic system
For a vaccine to prime de novo immune responses, naive T-cells and B-cells that reside in 
secondary lymphoid organs (lymph nodes and spleen) must be stimulated. Because of this 
localization, Zinkernagel first enunciated the “geographical” concept of immunity, whereby 
vaccines that do not reach the lymphoid organs are ignored by the immune system.27 Two 
pathways for vaccine delivery to lymph nodes are possible: First, vaccine molecules can be 
directly transported from injection sites (muscle, skin, or mucosal surfaces) to draining 
lymph nodes (LNs) by lymph draining through lymphatic vessels (Fig. 1). Alternatively, 
APCs (monocytes from the blood, or local tissue-resident dendritic cells) can internalize 
vaccine antigens/adjuvant compounds at the injection site and actively carry them through 
migration to the LNs. The latter pathway is relatively inefficient because few APCs migrate 
to lymph nodes from a site of inflammation, but these migratory cells play an important role 
in the evolving immune response in some settings.28 Bioconjugate strategies have thus been 
explored that facilitate lymphatic uptake and capture of vaccines in the lymph nodes.
2.1. Targeting lymphoid tissues via macromolecular conjugates
The fate of molecules injected parenterally is strongly influenced by molecular size. 
Connective tissues are perfused by blood and lymphatic vessels, which play a major role in 
the clearance of proteins injected into the tissue. Fluid is both released and reabsorbed across 
blood vessels, while lymphatic vessels provide for one-way transport of fluid out of tissue. 
Blood vessels reabsorb ~10-fold more interstitial fluid from the tissue than lymphatics, but 
the endothelial cells of the blood vessels are connected by tight junctions which block the 
diffusion of particles greater than ~3-5 nm in size. Thus, small molecules/particles are 
cleared from tissues primarily by the blood, while proteins show increasing efficiencies of 
lymphatic uptake with increasing molecular weight (plateauing at masses greater than 
~40-50 KDa).29,30 For vaccines, this size-dependent transport means that peptides, small 
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protein antigens, and a variety of molecular adjuvants will exhibit very poor lymph node 
accumulation if injected as unformulated compounds. Thus, a number of approaches have 
been developed to direct small molecular weight vaccine components to lymph nodes by 
increasing their effective hydrodynamic size.
Antigens and molecular adjuvants conjugated to size-optimized nanoparticles (NPs) have 
frequently been used to promote LN targeting. Reddy et al. showed that small polypropylene 
sulfide (PPS) NPs (less than 45 nm in diameter) were able to drain efficiently to lymph 
nodes for capture by LN-resident dendritic cells (DCs).31,32 Attaching subunit antigens or 
adjuvants to such particles enhanced both humoral and antigen-specific CD8+ T cell 
responses.32,33 Similar enhancements in immunogenicity were observed by Fifis et al. using 
peptide antigens conjugated to 40 nm diam. polystyrene nanoparticles.34,35 Using 
monodisperse polystyrene nanoparticles, Manolova et al. also demonstrated size-dependent 
trafficking of NPs to the draining LNs: large particles (200-500 nm) were mainly associated 
with DCs at the injection sites, but small particles (20-200 nm) were able to freely drain to 
the lymph node and accumulate in LN-resident DCs and macrophages, suggesting an 
optimum range for lymphatic uptake of injected nanoparticles.36 In each of these studies, 
subsequent conjugation of antigen or adjuvant to lymph node-targeting NPs led to markedly 
enhanced humoral and cell-mediated immune responses, demonstrating the potential of 
nano-sized materials in vaccination.
Conjugation to water-soluble polymers can also increase the hydrodynamic radius of 
compounds to promote lymphatic delivery. Because efficient lymph node accumulation is 
also needed for sentinel lymph node mapping in cancer (a procedure where optical or 
radioactive tracers with lymph node tropism are injected at a tumor site to identify tumor-
draining lymph nodes),37 a number of examples of lymph node-targeting conjugates 
applicable to vaccines have been demonstrated in the context of delivering imaging agents to 
lymph nodes. For example, Forrest and colleagues investigated LN retention of a series of 
six different molecular weight hyaluronan (HA)-near-infrared dye (HA-IR820) conjugates in 
mice over 2 weeks following subcutaneous injection.38 They discovered that 74 KDa HA-
IR820 had the largest net lymph node uptake. Enhanced lymphatic uptake and nodal 
retention of HA conjugates suggest this natural biodegradable polymer could be an 
interesting vaccine carrier, particularly given the fact that one of its receptors, CD44, is 
expressed by APCs. Recently, the use of polymer conjugates to enhance LN uptake by 
vaccines was shown for water-soluble N-trimethylaminoethylmethacrylate chitosan (TMC)-
protein antigen conjugates. TMC-antigen conjugates were shown to exhibit dramatic 
increases in lymph node uptake relative to soluble antigen after nasal instillation.39 The 
macromolecular conjugate also elicited 80-fold higher serum IgG responses compared to 
mixtures of the same polymer with antigen. These results suggest bioconjugates are also 
capable of targeting LN via mucosal routes of administration, when coupled to polymers 
such as chitosan that promote penetration through the epithelial barriers at these sites.39
Apart from size, surface properties (i.e. surface charge, hydrophobicity) can affect the 
delivery of macromolecules to the lymph node. It is widely believed that positively charged 
surface leads to strong electrostatic interaction with the negatively charged interstitial 
matrix, preventing lymphatic drainage. Thus, neutral or negatively charged molecules are 
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preferred in lymph node targeting. Takakura et al. demonstrated that neutral or anionic 
polymers were more efficiently accumulated in the draining lymph nodes compared to 
cationic polymers.40 In another study, Kaminskas et al. reported the influence of surface 
PEGylation of a polylysine dendrimer in the absorption and lymphatic targeting following 
SC administration in a rat model and found that increasing the PEG chain length (thereby 
shielding the surface charge) promoted uptake in the lymphatics.41 The Hydrophobicity of 
macromolecular carrier can impact the lymphatic uptake. Maintaining a balance between 
surface hydrophilicity and hydrophobicity has been shown to govern the drainage from 
injection sites and lymph nodes retention.42 Enhancing hydrophobicity leads to increased 
molecular interaction with antigen presenting cells, thus increasing lymph node retention. 
However, hydrophobic modification also limits the solubility and leads to aggregation at the 
injection sites, reducing the drainage to the lymphatics. Thus, balancing the hydrophobicity/
hydrophilicity is critical in designing molecular conjugates to target lymph nodes. 
Dendrimers are perhaps the most intensively investigated macromolecule for lymph node 
targeting purposes.43 These compact polymeric structures are in an optimal size range to 
avoid entry into blood vessels from tissue but still diffuse efficiently through the 
extracellular matrix. They are transported to the lymphatics and trapped in the lymph node, 
especially when their surface charge and hydrophobicity is appropriately modified. 
Kobayashi and colleagues investigated the use of gadolinium-conjugated poly(amido amine) 
(PAMAM) dendrimers as magnetic resonance lymphangiography agents.44 Increasing 
hydrophobicity of the dendrimer led to enhanced lymphatic uptake. The same group also 
conjugated 5-color near-infrared dyes and radionuclides to a generation-6 PAMAM 
dendrimer and successfully applied these polymers in multi-modal and multicolor lymphatic 
imaging.45 Together, materials that can efficiently target lymph node need to possess a small 
size (5-100 nm), negative or neutral surface charge, and appropriate hydrophobicity.
A second size-based strategy for lymph node targeting is to design conjugates that non-
covalently associate with serum proteins that have intrinsically efficient lymphatic uptake. 
The best-established example of this approach is ‘hitchhiking’ of dye compounds on 
endogenous albumin following parenteral injection for sentinel lymph node mapping: A 
variety of small-molecule dyes such as Evans blue were discovered empirically to stain 
draining lymph nodes when injected subcutaneously in tissues or in tumor resection sites, 
allowing visual identification of lymph nodes during tumor resection surgery.46 Subsequent 
structure-function analyses of effective dyes revealed a common characteristic of effective 
lymph node mapping dyes: high-affinity binding to albumin.47 Thus, upon injection, these 
compounds associate with endogenous albumin in the interstitial fluid, forming a complex of 
appropriate size to efficiently traffic to lymphatics. Inspired by this clinically-proven 
approach for lymph node targeting, we recently developed ‘albumin hitchhiking’ vaccines, 
where antigens or molecular adjuvants are covalently linked to a lipophilic albumin binding 
domain (Fig. 2a).48 These amphiphile-vaccines, if appropriately designed to reduce 
spontaneous cell membrane insertion while retaining effective association with albumin, 
exhibited >10-fold increased accumulation in lymph nodes following subcutaneous 
administration in mice (Fig. 2b-c). Our collective data to date suggests initial lymphatic 
uptake and lymph node targeting is largely a size-based effect, whereby albumin, which is 
large enough to show predominantly blood-to-lymph one-way trafficking out of tissues, 
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ferries the vaccine to lymph nodes. (Notably however, once in the lymph node, albumin 
binding may lead to significantly altered trafficking, uptake, and antigen processing 
compared to free vaccine). This greatly increased lymph node delivery in turn led to greatly 
enhanced potency of these vaccines for promoting T-cell responses (Fig. 2d) and anti-tumor 
immunity. In addition, this approach greatly increased the safety profile of molecular 
adjuvants by effectively confining them to draining lymph nodes, reducing systemic 
dissemination. Given the fact that lymph, which originates from interstitial fluid and 
circulates throughout the lymphatic system, contains many substances, including plasma 
proteins (i.e.—albumins, globulins, and fibrinogen), lipoproteins, complement components, 
etc., it remains to be investigated whether other lymph components can be similarly 
exploited for ‘hitchhiking’ of vaccines to lymph nodes.
2.2 Targeting immune cell receptors
In addition to the “passive targeting” strategies described above, which rely on the physical 
properties of vaccine carriers to promote lymphatic uptake, “active targeting” based on 
conjugation of vaccines with a specific ligand for APC surface receptors (e.g. Fc receptors, 
CD40, C-type lectin receptors such as DC-SIGN, DEC-205, mannose receptor, etc.) can also 
be used to augment lymph node retention.49-51 One of the first and most striking examples 
of the capacity of ligand-mediated targeting to promote vaccine responses was shown with 
protein antigens conjugated to an anti-DEC-205 antibody: anti-DEC-205-ovalbumin 
conjugates injected in mice were taken up by CD11c+ DCs primarily in the lymph nodes 
draining the injection site, leading to 400-fold greater CD8+ T-cell responses compared to 
non-targeted ovalbumin protein.51 Recently, human anti-DEC-205 antibody fused with NY-
ESO-1, a full-length cancer-testis antigen overexpressed in diverse cancer types, was shown 
to induce humoral and cellular immunity in patients with confirmed NY-ESO-1-expressing 
tumors.52 Other members of the C-type lectin receptors, including DC-SIGN (CD209) and 
the mannose receptor (CD206), recognize carbohydrates (mannose, fucose, glucose, 
maltose, etc.) that are characteristic of pathogen surfaces, regulating the uptake of pathogens 
and subsequent activation of adaptive immune responses. The high specificity of 
carbohydrate-lectin interactions has been exploited for targeting a wide variety of antigen/
adjuvant formulations for vaccine applications. For example, mannosylated MUC1, a tumor-
associated mucin-like protein has been shown to induce strong Th1 or Th2 immune 
responses, depending on the oxidative state of the mannose.53,54 Clinical studies with 
oxidized mannan (a polymeric form of mannose)–MUC-1 conjugates demonstrated 
induction of both humoral and cellular responses and evidence of protection against 
recurrence in early stage breast cancer patients.55 Importantly, no adverse events were 
observed, suggesting these polymer conjugates were safe in humans. Synthetic artificial 
ligands, such as nucleic acid aptamers identified by in vitro selection, have also been shown 
to specifically bind DEC-205 on DCs.56 Due to their unique chemical properties and low 
immunogenicity, aptamers are promising alternatives to antibody-based targeting agents. 
The DEC-205-targeted antigen was efficiently cross-presented and subsequently activated 
CD8+ T cells.56 Clearly, active targeting to DCs enhances vaccine efficacy and safety and 
might be included in the future as a safe immunotherapy regimen.
Liu and Irvine Page 6
Bioconjug Chem. Author manuscript; available in PMC 2015 December 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
These two concepts of hydrodynamic size and receptor-specific targeting can also be 
combined for enhanced LN targeting: Lymphoseek, a mannose-conjugated, dextran-based 
lymphatic mapping polymeric agent has been recently approved by the FDA to assist in the 
localization of lymph nodes draining a primary tumor site in patients with breast cancer or 
melanoma.57 Lymphoseek has an appropriate size (7 nm) and carries multiple units of 
mannose, which targets mannose receptors expressed on the surface of macrophages and 
DCs.
3. Promoting antigen processing and presentation
Antigen presentation by APCs, whereby short peptide fragments of antigens are loaded into 
MHC molecules and displayed on the APC surface to activate T-cells, plays a key role in the 
induction of adaptive immune responses. Many of the targeting ligands discussed above for 
promoting lymph node accumulation that can bind to APC surface receptors promote 
antigen internalization or modulate antigen processing.49-51,53-55,58,59 However, 
bioconjugate vaccines can be further designed to control antigen presentation by influencing 
what intracellular compartments antigens are delivered to within APCs or directly changing 
how antigens are proteolyzed and loaded onto MHC molecules.
3.1. Bioconjugate vaccines promoting cross presentation
Much effort has focused on promoting MHC-I presentation of antigens, in order to prime 
CD8+ T-cell responses with vaccines. Class I MHC molecules are normally primarily loaded 
with peptides generated in the cytosol, and thus antigens taken up from the extracellular 
environment (and therefore transported into endosomes within APCs) are typically not 
delivered to the MHC I antigen loading pathway. The process of extracellular antigens being 
taken up by APCs and loaded on class I MHC is called cross presentation, a process that 
may be critical for successful subunit vaccines against cancer and some infectious 
diseases.60 One strategy to enhance class I MHC loading is to link antigens to endosome-
disrupting moieties that can deliver the macromolecules to the cytosol. For example, Stayton 
and colleagues prepared pH-responsive, endosomolytic polymers to actively promote 
antigen cross-presentation, based on amphiphilic diblock copolymers conjugated with 
protein antigens through disulfide linkages (Fig. 3).61-63 In this elegant design, protonation 
of the carboxylate and amine groups of these copolymers within endolysosomes leads to 
their interaction with the endosomal membrane and/or a proton sponge effect, leading to 
escape of the conjugates into the cytosol, where the disulfides are reduced to release the 
antigen for “natural” class I MHC pathway processing.61 These copolymers yielded 
markedly enhanced cellular responses in vivo.61-63 The vaccine's efficacy was further 
improved when CpG DNA (a molecular adjuvant that stimulates APCs) was included.61 
Another strategy explored for cytosolic delivery of antigens is through conjugation to cell-
penetrating peptides (CPPs). Certain CPPs are endosomolytic and conjugation of short 
(~10-20 amino acid) CPP sequences to antigens has been shown to promote antigen uptake, 
cytosolic localization, and antigen cross-presentation for potent cytotoxic CD8+ T cell 
responses in vivo.64-66 Finally, activation of certain pattern-recognition receptors (reviewed 
in the following section) enables efficient antigen cross-presentation via diverse 
mechanisms, leading to potent CD8+ T cell stimulation.67 In summary, bioconjugates can be 
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designed to dramatically enhance antigen uptake and presentation, resulting in much lower 
antigen doses required for immune cell activation and robust and T-cell proliferation.
3.2. Promoting tolerogenic antigen presentation
In addition to stimulating an immune response, bioconjugates can be used to promote 
tolerogenic antigen presentation, in order to inhibit detrimental immune responses. This is a 
potentially ideal treatment strategy for autoimmune diseases, allergies, and organ 
transplants, providing antigen-specific immune tolerance without global 
immunosuppression. Early studies focused on the use of apoptotic cells for the induction of 
tolerance: Peptide self-antigens chemically conjugated to apoptotic cells were shown to be 
effective and safe for the prevention and treatment of a wide variety of autoimmune diseases 
including relapsing experimental autoimmune encephalomyelitis (EAE, a mouse model of 
multiple sclerosis),68 type 1 diabetes69 and transplant rejection.70 Although the underlying 
mechanisms are still under study, it is believed that several distinctive mechanisms, such as 
suppression of costimulatory molecule expression on APCs, modulation of antigen 
presentation, and production of immunosuppressive cytokines to promote T-cell clonal 
depletion or anergy may act synergistically in such therapies. Recently, nanoparticles 
conjugated with disease-associated peptide antigens were used to replace donor cells in this 
approach in an attempt to avoid the complexities and cost associated with cell manipulation 
in the clinic. A number of different nanoparticles have been covalently conjugated to 
autoantigens and have shown promise in several autoimmune disease models.71,72 For 
example, Getts and coworkers showed that intravenous infusion of antigen-decorated 
particles (500-nm diameter) induced long-term T-cell tolerance in mice with relapsing 
experimental autoimmune encephalomyelitis (EAE).72 Blockade of immune cell adhesion 
during antigen recognition has been shown to suppress the inflammatory immune response 
in autoimmune diseases. Chittasupho and colleagues used peptide-conjugated nanoparticles 
to block immunological synapse formation between dendritic cells and T-cells. These 
nanoparticles also altered cytokine production in cell culture when compared to 
unconjugated ligands.73 In a separate study, soluble antigen arrays (SAgAs, hyaluronic acid 
grafted with antigen and LABL peptide, an immune cell adhesion inhibitor) were shown to 
be efficacious in experimental autoimmune encephalomyelitis.74 Promoting tolerogenic 
antigen presentation has also been achieved by in situ binding of autoantigens to red blood 
cells. Kontos and coworkers reported an innovative strategy where an antigen was 
conjugated with an erythrocyte binding domain, with the goal of targeting autoantigens into 
the normal pathways of tolerance present during clearance of aging red blood cells.75 
Following i.v. injection, these RBC-binding constructs bound efficiently to erythrocytes in 
the blood, inducing peripheral tolerance in an antigen specific manner.75 Instead of using 
cells, this strategy uses molecularly-defined bioconjugates for in situ erythrocyte targeting, 
which like the nanoparticle/microparticle-conjugate approach, should be more readily 
translated to human studies.
4. Multivalent immunogens
Many pathogens such as viruses and bacteria exhibit a highly ordered, repetitive display of 
antigens on their surfaces, which are thought to effectively engage and cluster antigen 
Liu and Irvine Page 8
Bioconjug Chem. Author manuscript; available in PMC 2015 December 29.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
receptors on B cells, stimulating antibody production more strongly than the same antigens 
encountered as soluble proteins in solution.76-78 These observations have led to the idea that 
the immunogenicity of subunit antigens can be greatly enhanced by a rigid, ordered 
organization on surfaces, mimicking viral particles.76 This multivalency of antigen 
presentation, together with the facilitation of immune cell recognition and antigen 
internalization, has been explored as a strategy to enhance both humoral and cellular 
immunity.
4.1. Multivalent antigens
Early studies with haptens (small molecule antigens that elicit T-cell-independent B-cell 
responses) conjugated to water-soluble polymers suggested that T-independent antibody 
responses in vivo are only elicited when at least ~20 haptens are coupled to each polymer 
chain at a spacing of ~10 nm apart,79 providing early evidence for the importance of antigen 
multivalency and clustering in B-cell triggering. Building on the principle that multivalency 
can increase the immunogenicity of subunit antigens, it was shown that peptides 
multimerized on a dendritic oligo-lysine scaffold (termed multiple antigenic peptides, 
MAPs) elicited enhanced antibody responses.80 Mixing immunological adjuvants or 
incorporating T-helper epitopes into the MAP system have been reported to greatly enhance 
the efficacy of these vaccines.81 MAPs can be readily constructed using solid phase peptide 
synthesis and have been shown to be effective in a variety of vaccines.82,83 Dendrimers are a 
second platform widely used for multivalent antigen display. For example, Sheng et al. 
prepared polyamidoamine (PAMAM) dendrimers chemically conjugated to ovalbumin and 
found significant increases in both anti-OVA CD8+ T cells and OVA-specific IgG in mice 
compared to soluble OVA vaccines.84 Liu et al. reported a star polymer-peptide conjugate 
and found greatly enhanced cellular responses without the need for additional 
immunological adjuvants.85 These self-adjuvanting conjugates were able to eradicate TC-1 
tumors (a model of HPV-induced cervical cancer) in mice after a single immunization.85 
Multimeric antigens can be also built on synthetic peptides linked with a polymerizable 
double bond86,87 or derived from ring-opening metathesis polymerization (ROMP).88 For 
example, Brandt et al. demonstrated a linear polypeptide derived from acryloyl modified 
monomer had improved immunogenicity.87 Using a polymer-hapten conjugate system 
derived from ROMP, Kiessling et.al., demonstrated that B cell activation was strongly 
influenced by antigen valency; conjugates with high antigen valencies promoted stronger B 
cell receptor signaling in vitro and greater antibody production in vivo.88 These studies, 
provide evidence that antigen conjugates in a multivalent format can yield potent B- and T-
cell responses.
4.2. Self-assembled immunogens
As an alternative to direct conjugation/synthesis of pre-fabricated multivalent scaffolds, 
multivalent immunogen display can also be achieved using individual antigens that undergo 
programmed self-assembly. The licensed hepatitis B virus and human papilloma virus 
vaccines are based on natural self-assembling proteins from viral capsids, which self-
assemble to form nanoparticles 40-60 nm in diameter displaying an ordered array of HBV 
and HPV antigens, respectively.89 Recently, fully synthetic peptides have been explored as 
self-assembling vaccine nanomaterials. For example, synthetic lipopeptides, containing 
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peptide antigens linked to a lipid-like molecule, are capable of self-assembling into 
homogeneous nanoparticles90 (Fig. 4A) or cylindrical micelles91 (Fig. 4B) via hydrophobic 
interactions. In addition to lipid conjugation, antigen epitopes may also be covalently linked 
to peptide sequences that form ordered structures via molecular interactions including van 
der Waals forces, ionic bonds, hydrogen bonds and hydrophobic forces.92-95 Engineered 
peptide nanoparticles92 (Fig. 4C) or nanofibers93-95 (Fig. 4D) with repetitively displayed 
antigen epitopes have been assembled utilizing the peptide molecular interactions and have 
shown to be potent immunogens promoting both T-cell and antibody responses in vivo. A 
common characteristic of these virus-like synthetic assemblies is their potency without the 
need for addition of further adjuvants.91,94 This finding is even more striking given that 
responses to these nanostructures have been formally shown to be independent of common 
Toll like receptor-based innate immune recognition pathways.91,93 Yet these self-assembling 
antigens elicit T-cell dependent, long-lived class-switched antibody responses,96 implying 
that humoral immunity primed by these multivalent immunogens shares characteristics of 
both T-cell-independent and T-cell-dependent antigens.
Self-assembling nanostructures can be designed to incorporate additional functionality 
beyond antigen display alone. For example, coupling of antigens to particles through a 
disulfide linkage promotes environment-sensitive release of the antigen for antigen 
processing in the reductive endolysosomal pathway within APCs 97; this approach has been 
used to link protein antigen to block copolymer micelles for intracellular release of antigen, 
promoting cross presentation to T-cells.98 Moyle et al. developed an approach to couple 
protein antigens to nanoparticle-forming amphiphiles that self-assembled via hydrophobic 
lipid tails.99 The lipid tails of these multi-block amphiphiles were also designed to trigger 
Toll-like receptors on APCs (discussed further below) and the hydrophilic block contained a 
dendritic cell-targeting peptide, thus building antigen display, APC targeting, and APC 
activation all into a single molecule. These diverse examples illustrate the capacity of 
nanostructure-based vaccine platforms to display ordered arrays of antigen and regulate 
antigen uptake and processing, using self-assembly-based synthesis approaches that are 
attractive for well-defined large-scale manufacturing.
5. Activating antigen presenting cells
As noted in the introduction, subunit antigens are usually formulated with adjuvants to boost 
or modify the immune response, but only a handful of adjuvants have reached licensure as 
part of approved vaccines so far. One of the main ways by which adjuvants can act is to 
stimulate the activation of antigen presenting cells and other innate immune cells, which 
play critical roles in initiating the adaptive immune response (Figure 1). APC activation is 
driven by pathogen-sensing receptors that recognize conserved molecular motifs from 
microbes such as lipopolysaccharide, double-stranded RNA, and cyclic dinucleotides, and 
such “danger signal” molecules have been widely exploited as molecular adjuvants for 
vaccines.100 The simplest bioconjugation strategy to exploit danger signals in vaccine design 
is to conjugate these molecular adjuvants directly to antigens, enforcing co-exposure of 
immune cells to the antigen and danger signal together.101-106 However, more sophisticated 
chemical strategies to modulate the form and function of molecular adjuvants may lead to 
adjuvant compounds with entirely new properties and potencies.107
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The most studied class of danger signals are ligands for a highly conserved family of 
receptors known as the Toll-like receptors (TLRs), which are expressed by immune cells in 
organisms ranging from flies to humans.101 TLR agonists are being employed in a variety of 
novel ways by chemists to enhance prophylactic or therapeutic vaccines. For example, 
irradiated tumor cells have been pursued in numerous clinical trials as candidate cancer 
vaccines. Tom et al. synthesized succinimidyl ester-functionalized CpG DNA and 
lipoteichoic acid, ligands for TLR-9 and TLR-2/6, respectively, and conjugated these 
reactive ligands to cell surface proteins of tumor cells to provide danger signals that would 
be guaranteed to be co-delivered into APCs during vaccination.108 Multimerization of TLR 
agonists may also impact their function, by promoting receptor aggregation that alters 
intracellular signaling. Mancini et al. showed that heterodimers of TLR-2 and TLR-9 
agonists coupled via short poly(ethylene glycol) spacers endowed these danger signals with 
a potent capacity to activate NF-κB signaling in APCs, while soluble mixtures of the same 
ligands had almost no capacity to trigger this signaling network; this alteration of 
intracellular signaling led to enhanced production of T-cell-stimulatory cytokines from 
APCs.109 Covalently link small-molecule immune response modifiers (IRMs) to antigens is 
a popular strategy to improve vaccine potency and adjuvant safety.102,103 Recently, a 
rational approach which precisely control the pharmacology of IRMs was developed.110 
IRMs were modified with polyethylene glycol (PEG) linker and terminal phophonate 
groups. While PEG linker improves solubility at neutral pH, the phophonate group 
facilitates the adsorption to Al(OH)3, restricting the systemic exposure. This conjugate 
design leaded to increased in vivo potency with little or no systemic toxicity.110
Supramolecular approaches may open new opportunities for adjuvant design. For example, 
synthetic peptides of the general sequence CSKKK containing one or more palmitoyl groups 
appended to the cysteine thiol or N-terminus are agonists of TLR-2. These amphiphiles have 
recently been shown to self-assemble as spherical or cylindrical micelles in solution 
depending on the number of lipid tails;111 if stable in physiologic conditions, these different 
structures could have significant implications for crosslinking of the receptors. A 
structurally optimized TLR-2 specific monoacyl lipopeptide was also developed recently 
with excellent adjuvant activity, safety and also water solubility.112 Type A CpG single-
stranded oligonucleotides (ligands for TLR-9) with palindromic nucleotide sequences are 
known to potently induce the production of type I interferons (IFNs), key cytokines 
promoting cellular and humoral immunity. However, the large-scale homogeneous 
production of these oligos, which undergo uncontrolled base pairing-mediated aggregation 
and self-assembly, is problematic. Gungor et al. recently demonstrated that non-palindromic 
CpG oligos could be induced to self-assemble by condensation with cationic peptides 
(derived from the Tat protein of HIV), forming well-defined “nanorings” that induced strong 
IFN induction in dendritic cells, mimicking palindromic CpGs with a well-defined 
nanomaterial.113 The development of nucleic acid-based adjuvants is an area where the 
burgeoning field of DNA nanotechnology is ripe to have impact, given the capacity of self-
assembled DNA to form arbitrary, complex nanoscale structures. Early examples of CpG 
delivered by nanosized DNA assemblies suggest that uptake and stimulation of TLR-9 can 
be fine-tuned by DNA nanostructures.114-116
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6. Conclusions and future outlook
The rational design of next-generation prophylactic and therapeutic vaccines will benefit 
substantially from breakthrough advances in multidisciplinary fields including basic 
immunology, engineering, chemistry and materials science. By linking two or more 
molecules to form a complex having diverse functions absent in the individual components, 
bioconjugate strategies provide exciting new ways to modulate the induction of immunity or 
tolerance, bridging immunological features with a detailed understanding of synthetic 
molecular functions. While this review outlines the bioconjugate approaches currently being 
used to optimize vaccine efficacy, it underscores the promise of bioconjugates in the 
development of future innovative vaccines. Undoubtedly as we gain more knowledge of the 
human immune system, additional bioconjugate strategies not covered in this review will 
emerge as new modalities for immune modulation. For example, bioconjugates might be 
developed for immune checkpoint blockade to augment vaccine immunity. Bioconjugates 
might also be engineered to program immune cellular differentiation and thus control 
immune cell fates; or be used to mimic the antigen exposure kinetics of pathogens. In 
addition, new types of bioconjugates fulfilling the above design criteria are also emerging as 
novel vaccines or delivery systems. Therefore, future strategies to design bioconjugates that 
can produce tailored immune responses against a specific disease will require an extension 
of our current understanding of how to modulate the immune system. In the long term, 
bioconjugates will continue to play key roles in rational design for improvement of our 
current vaccines and for development of new vaccines against challenging pathogens and 
diseases.
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Figure 1. Mechanisms by which bioconjugates enhance the activation of immune system through 
vaccination
Activation of the immune response begins when vaccines are introduced to the body. 
Bioconjugates have been engineered to target vaccines to antigen-presenting cells (APCs) in 
the lymph node (1); to enhance the antigen uptake and presentation (2); and to activate 
APCs (3).
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Figure 2. Targeting lymph nodes with ‘albumin-hitchhiking’ vaccines
a) Schematic of the design of albumin-binding amphiphiles. Antigen-amphiphiles contain a 
lipophilic albumin-binding diacyl lipid tail, PEG solubilizing linker and a vaccine cargo 
(peptide or other antigen, or adjuvant compound). b-c) Fluorophore-conjugated amphiphiles 
were injected s.c. in mice, and draining LNs were isolated and imaged 24 hours post 
injection. Albumin-binding amphiphiles accumulated in LNs in a lipid- (b, fixed PEG length 
48 EG units) and PEG- (c, fixed C18 diacyl lipid tails) molecular weight-dependent manner. 
d) Following vaccination, ‘albumin-hitchhiking’ vaccines (“Lipo” conjugates) elicited 
enhanced antigen-specific CD8+ T-cells responses compared to traditional peptide vaccines 
adjuvanted with the Toll-like receptor agonist CpG DNA. Shown are frequencies of antigen-
specific cytokine-producing T-cells among all CD8+ T-cells in peripheral blood 7 days post 
boost. Reprinted by permission from Macmillan Publishers Ltd: ref. 48, copyright 2014.
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Figure 3. Synthesis and antigen conjugation of pH-responsive endosomolytic polymers for 
vaccine delivery
a) Amphiphilic diblock copolymers were constructed with a hydrophilic block for antigen 
conjugation and a hydrophobic/endosomolytic block for promoting cytosolic antigen 
delivery. b), conjugation of ovalbumin (ova) antigen to the diblock polymeric carriers (pol) 
of panel (a) promoted MHC class I antigen presentation, as read out by production of LacZ 
(reported as an optical density at 570 nm) by a T-cell hybridoma reporter cell line incubated 
with dendritic cells loaded with the antigen. c) Dual delivery of ova antigen and CpG 
adjuvant on the pH-responsive polymer conjugate enhanced cellular responses in vivo, as 
determined by measuring the frequency of IFN-γ-producing CD8+ T-cells following 
immunization. Reprinted with permission from ref. 61, Copyright (2013) American 
Chemical Society.
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Figure 4. Monomeric peptides self-assemble into multivalent nanostructures
a and b) Lipid-conjugated peptide amphiphiles self-assemble into spherical (a) and 
cylindrical micelles (b). c and d) Peptides with intrinsic self-assembling properties provide a 
platform for multivalent display of antigens in nanoparticle (c) and nanofiber platforms (d). 
Reproduced with permission from ref. 90 (a), Copyright 2011 John Wiley & Sons Ltd; ref. 
91 (b), Copyright 2012 John Wiley & Sons Ltd; ref. 92 (c), Copyright 2009. The American 
Association of Immunologists, Inc. and ref. 95 (d), Copyright 2014 Macmillan Publishers 
Ltd.
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